Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

被引：0
|
作者：
Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
机构：
[1] Iran University of Medical Science (IUMS),Endocrine Research Center, Institute of Endocrinology and Metabolism
[2] Iran University of Medical Sciences (IUMS),Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism
来源：
BMC Cancer | / 21卷
关键词：
Peptide receptor radionuclide therapy; Radioiodine refractory-differentiated thyroid Cancer; Medullary thyroid carcinoma; Papillary thyroid carcinoma; Yttrium-90; 177Lu-DOTATATE; Indium-111; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Lenvatinib in Radioiodine-Refractory Thyroid Cancer
    Lee, Hyo Jin
    Yun, Hwan-Jung
    Kim, Samyong
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (19): : 1868 - 1868
  • [22] Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences
    Masaki, Chie
    Sugino, Kiminori
    Saito, Naoko
    Akaishi, Junko
    Hames, Kiyomi Y.
    Tomoda, Chisato
    Suzuki, Akifumi
    Matsuzu, Kenichi
    Uruno, Takashi
    Ohkuwa, Keiko
    Kitagawa, Wataru
    Nagahama, Mitsuji
    Ito, Koichi
    THYROID, 2020, 30 (02) : 214 - 221
  • [23] Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?
    Hayes, A. R.
    Crawford, A.
    Al Riyami, K.
    Tang, C.
    Wild, D.
    Khoo, B.
    Caplin, M.
    Nicolas, G.
    Grossman, A. B.
    NEUROENDOCRINOLOGY, 2019, 108 : 273 - 273
  • [24] New approaches for patients with advanced radioiodine-refractory thyroid cancer
    Pitoia, Fabian
    Jerkovich, Fernando
    Trimboli, Pierpaolo
    Smulever, Anabella
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (01): : 9 - 27
  • [25] Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
    Hayato, Seiichi
    Shumaker, Robert
    Ferry, Jim
    Binder, Terri
    Dutcus, Corina E.
    Hussein, Ziad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) : 971 - 978
  • [26] Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
    Weitzman, Steven P.
    Sherman, Steven, I
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 253 - +
  • [27] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
    Lindner, C.
    Dierneder, J.
    Pall, G.
    Pirich, C.
    Hoffmann, M.
    Raderer, M.
    Becherer, A.
    Niederle, B.
    Lipp, R.
    Lind, P.
    Gallowitsch, H.
    Romeder, F.
    Virgolini, I.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
  • [28] Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
    Cabanillas, Maria E.
    Takahashi, Shunji
    SEMINARS IN ONCOLOGY, 2019, 46 (01) : 57 - 64
  • [29] Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
    Brose, Marcia S.
    Worden, Francis P.
    Newbold, Kate L.
    Guo, Matthew
    Hurria, Arti
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2692 - +
  • [30] Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
    Worden, Francis
    Fassnacht, Martin
    Shi, Yuankai
    Hadjieva, Tatiana
    Bonichon, Franoise
    Gao, Ming
    Fugazzola, Laura
    Ando, Yuichi
    Hasegawa, Yasuhisa
    Park, Do Joon
    Shong, Young Kee
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Meinhardt, Gerold
    Schlumberger, Martin
    Brose, Marcia S.
    ENDOCRINE-RELATED CANCER, 2015, 22 (06) : 877 - 887
12345